What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?
December 23, 2025 |
Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.
Lucy McKay Megan Pullein
CEO Strategic Operations Officer
Medics for Rare Disease Medics for Rare Disease
Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?
Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.
Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.
Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?
Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.
Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?
Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.
Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.
Christy: Where does the work for each group start, and where does it end?
Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?
The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.
The final phase will be to consolidate this evidence into concrete recommendations.
Christy: What do you find most exciting about RDI-Lancet Commission?
Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.
It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.
Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.
For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract
About Medscape Education
Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
Impacting Lives with Rare Disease Education
Education on rare diseases is crucial. Estimates suggest there are approximately 10,000 rare diseases, with 263–446 million people affected worldwide.Since its launch in September 2022, the Medscape Pathways in Rare...
Medscape’s Virtual Patient Simulation Makes a Significant Impact on Real-World Treatment Selection for T2D
An analysis of data using Real-World Outcomes showed that a virtual patient simulation had a significant effect on real-world treatment selection for T2D. The paper, published in JMIR Medical Education,...
A Rare Disease Update from Medscape Education
A Novel Provider Education Module to Enhance Detection of Alpha-1 Antitrypsin Deficiency
New Outcomes Are a Breath of Fresh Air at ERS
ERS 2023 will mark the new release of outcomes data by Medscape Education Global. During the poster hall sessions on September 12, the Medscape team will present a poster that...
Medscape Education Launches 20th Older Driver Safety Educational Program
Education Supported by the National Highway Traffic Safety Administration
Protecting the Heart Through Education at ESC 2023
Medscape Education Global is joining cardiology professionals from across Europe for ESC 2023 in Amsterdam. This year’s congress theme is “Joining Forces to Protect the Heart,” and Medscape will be...
Medscape’s Rare Disease Learning Center Has Reached 1 Million Learners
The Pathways in Rare Disease Learning Center celebrates a momentous achievement - engaging one million learners in its educational initiatives. This milestone signifies a profound impact on clinician confidence in...
Continuing Medical Education Outcomes are Much More Than Statistical Significance
At Medscape Education, we hold ourselves to the highest standards when it comes to analysing our programs. Our approach is unparalleled, employing a precise paired method that ensures we measure the...
The Most Important Person in the Room—A Look at Patient -Centricity at EHA
Across all of healthcare, a greater focus is being placed on patient centricity in order to improve outcomes and enhance patients’ quality of life. Although patient centricity is necessary in...
Innovation in Education Leads to Positive Outcomes at EAN 2023
The Medscape team recently returned from the 9th Annual Congress of the European Academy of Neurology (EAN) in Budapest, Hungary. Among the various highlights of the congress, the team showcased...